By: Kassi Filkins
From a phase 3 durability readout for a first-in-class TKI to a new interchangeable ranibizumab biosimilar and a deep dive into geographic atrophy management, June brought a wide-ranging mix of regulatory, clinical, and practice-pattern news for retina specialists
June leaned heavily on geographic atrophy (GA) and anti-VEGF durability, alongside a marquee phase 3 readout and a new biosimilar approval. Below is an overview of 6 key items from June 2026.